المؤلفون: Pien, Grace W, Ye, Lichuan, Keenan, Brendan T, Maislin, Greg, Björnsdóttir, Erla, Arnardottir, Erna Sif, Benediktsdottir, Bryndis, Gislason, Thorarinn, Pack, Allan I

المساهمون: 1 Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA Show more 2 Northeastern Univ, Sch Nursing, Bouve Coll Hlth Sci, Boston, MA 02115 USA Show more 3 Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA 4 Landspitali, Dept Sleep, Reykjavik, Iceland Show more 5 Univ Iceland, Sch Hlth Sci, Fac Med, Reykjavik, Iceland Show more 6 Univ Penn, Dept Med, Div Sleep Med, Perelman Sch Med, Philadelphia, PA 19104 USA

مصطلحات موضوعية: Kæfisvefn, PAD12, NAF12, Sleep Apnea, Obstructive

الوصف: To access publisher's full text version of this article click on the hyperlink below ; STUDY OBJECTIVES: Distinct clinical phenotypes of obstructive sleep apnea (OSA) have been identified: Disturbed Sleep, Minimally Symptomatic, and Sleepy. Determining whether these phenotypes respond differently to standard treatment helps us to create a foundation for personalized therapies. We compared responses to positive airway pressure (PAP) therapy in these clinical OSA phenotypes. METHODS: The study sample included 706 patients from the Icelandic Sleep Apnea Cohort with moderate-to-severe OSA who were prescribed PAP. Linear and logistic mixed models were used to compare 2-year changes in demographics, comorbid diseases, and sleep-related health issues within and across OSA clinical phenotypes. Relationships between changes in symptoms and PAP adherence were also examined. RESULTS: Overall, effect sizes were moderate to large when comparing sleepiness, insomnia-related, and apneic symptom changes in the Sleepy group with changes in other two groups, especially those in the Minimally Symptomatic group. Within the Disturbed Sleep group, PAP users and nonusers demonstrated similar changes in insomnia-related symptoms. The Minimally Symptomatic group remained relatively asymptomatic, but reported significant decreases in daytime sleepiness and physical fatigue; PAP users generally had larger improvements. The Sleepy group had reductions in nearly all measured symptoms, including large reductions in drowsy driving; almost all of these improvements were greater among PAP users than nonusers. CONCLUSIONS: OSA treatment response patterns differed by initial clinical phenotype and PAP adherence. Individuals with insomnia-related symptoms may require additional targeted therapy for these complaints. These findings underscore the need for a personalized approach to management that recognizes patients with a range of OSA presentations. ; National Institutes of Health

العلاقة: https://www.ncbi.nlm.nih.gov/pmc/journals/369Test/; Changing Faces of Obstructive Sleep Apnea: Treatment Effects by Cluster Designation in the Icelandic Sleep Apnea Cohort 2018 Sleep; http://hdl.handle.net/2336/620555Test; Sleep

الإتاحة: https://doi.org/10.1093/sleep/zsx201Test
http://hdl.handle.net/2336/620555Test

المؤلفون: Carlsen, Hanne Krage, Bäck, Erik, Eneroth, Kristina, Gislason, Thorarinn, Holm, Mathias, Janson, Christer, Jensen, Steen Solvang, Johannessen, Ane, Kaasik, Marko, Modig, Lars, Segersson, David, Sigsgaard, Torben, Forsberg, Bertil, Olsson, David, Orru, Hans

المساهمون: 1 Umea Univ, Dept Publ Hlth & Clin Med, Occupat & Environm Med, Umea, Sweden Show the Organization-Enhanced name(s) 2 Univ Iceland, Engn & Nat Sci, Reykjavik, Iceland Show the Organization-Enhanced name(s) 3 Univ Gothenburg, Inst Med, Sect Occupat & Environm Med, Dept Publ Hlth & Community Med,Sahlgrenska Acad, Gothenburg, Sweden 4 Environm Adm, Gothenburg, Sweden 5 Environm & Hlth Adm, Stockholm, Sweden Show the Organization-Enhanced name(s) 6 Univ Iceland, Fac Med, Reykjavik, Iceland 7 Landspitali Natl Univ Hosp Iceland, Dept Resp Med & Sleep, Reykjavik, Iceland 8 Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Uppsala, Sweden Show the Organization-Enhanced name(s) 9 Aarhus Univ, Dept Environm Sci, Roskilde, Denmark Show the Organization-Enhanced name(s) 10 Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway Show the Organization-Enhanced name(s) 11 Univ Tartu, Inst Phys, Tartu, Estonia Show the Organization-Enhanced name(s) 12 Umea Univ, Div Occupat & Environm Med, Dept Publ Hlth & Clin Med, Umed, Sweden 13 Swedish Meteorol & Hydrol Inst, Norrkoping, Sweden Show the Organization-Enhanced name(s) 14 Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark Show the Organization-Enhanced name(s) 15 Univ Tartu, Dept Family Med & Publ Hlth, Tartu, Estonia

مصطلحات موضوعية: Loftmengun, Hávaðamengun, Mengun, Bílar, Umferðarmannvirki, PAD12, Air Pollution, Motor Vehicles, Noise, envir, demo

الوصف: To access publisher's full text version of this article click on the hyperlink below ; Few studies have investigated associations between self-reported and modelled exposure to traffic pollution. The objective of this study was to examine correlations between self-reported traffic exposure and modelled (a) NOx and (b) traffic proximity in seven different northern European cities; Aarhus (Denmark), Bergen (Norway), Gothenburg, Ulna and Uppsala (Sweden), Reykjavik (Iceland), and Tartu (Estonia). We analysed data from the RHINE III (Respiratory Health in Northern Europe, www.rhine.nu) cohorts of the seven study cities. Traffic proximity (distance to the nearest road with >10,000 vehicles per day) was calculated and vehicle exhaust (NOx) was modelled using dispersion models and land-use regression (LUR) data from 2011. Participants were asked a question about self-reported traffic intensity near bedroom window and another about traffic noise exposure at the residence. The data were analysed using rank correlation (Kendall's tau) and inter-rater agreement (Cohen's Kappa) between tertiles of modelled NOx and traffic proximity tertile and traffic proximity categories (0-150 metres (m), 150 -200 m, >300 m) in each centre. Data on variables of interest were available for 50-99% of study participants per each cohort. Mean modelled NOx levels were between 6.5 and 16.0 mu g/m(3); median traffic intensity was between 303 and 10,750 m in each centre. In each centre, 7.7-18.7% of respondents reported exposure to high traffic intensity and 3.6-16.3% of respondents reported high exposure to traffic noise. Self-reported residential traffic exposure had low or no correlation with modelled exposure and traffic proximity in all centres, although results were statistically significant (tau = 0.057-0.305). Self reported residential traffic noise correlated weakly (tau = 0.090-0.255), with modelled exposure in all centres except Reykjavik. Modelled NOx\] had the highest correlations between self-reported and modelled traffic .

العلاقة: http://hdl.handle.net/2336/620349Test

الإتاحة: http://hdl.handle.net/2336/620349Test

المؤلفون: Campbell, B, Raherison, C, Lodge, C J, Lowe, A J, Gislason, T, Heinrich, J, Sunyer, J, Gómez Real, F, Norbäck, D, Matheson, M C, Wjst, M, Dratva, J, de Marco, R, Jarvis, D, Schlünssen, V, Janson, C, Leynaert, B, Svanes, C, Dharmage, S C

المساهمون: 1 Univ Melbourne, Ctr Epidemiol & Biostat, Allergy & Lung Hlth Unit, Melbourne, Vic, Australia Show the Organization-Enhanced name(s) 2 Univ Bordeaux Segalen, Unite Epidemiol & Biostat, Bordeaux, France Show the Organization-Enhanced name(s) 3 Murdoch Childrens Res Inst, Melbourne, Vic, Australia Show the Organization-Enhanced name(s) 4 Landspitali Univ Hosp, Dept Resp Med & Sleep, Reykjavik, Iceland Show the Organization-Enhanced name(s) 5 Univ Iceland, Fac Med, Reykjavik, Iceland Show the Organization-Enhanced name(s) 6 Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 1, Neuherberg, Germany Show the Organization-Enhanced name(s) 7 Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Inst & Outpatient Clin Occupat Social & Environm, Munich, Germany Show the Organization-Enhanced name(s) 8 Ctr Res Environm Epidemiol CREAL, Barcelona, Spain Show the Organization-Enhanced name(s) 9 CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain Show the Organization-Enhanced name(s) 10 Univ Pompeu Fabra, Dept Ciencies Expt & Salut UPF, Barcelona, Spain Show the Organization-Enhanced name(s) 11 Haukeland Hosp, Dept Occupat Med, Bergen, Norway Show the Organization-Enhanced name(s) 12 Univ Bergen, Ctr Int Hlth, N-5020 Bergen, Norway Show the Organization-Enhanced name(s) 13 Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden Show the Organization-Enhanced name(s) 14 Helmholtz Zentrum Munchen, CPC, Inst Lung Biol & Hlth iLBD, Munich, Germany Show the Organization-Enhanced name(s) 15 Swiss Trop & Publ Hlth Inst, Epidemiol & Publ Hlth, Basel, Switzerland Show the Organization-Enhanced name(s) 16 Univ Basel, Basel, Switzerland Show the Organization-Enhanced name(s) 17 Univ Verona, Epidemiol & Med Stat, Verona, Italy Show the Organization-Enhanced name(s) 18 Imperial Coll, Natl Heart & Lung Inst, London, England Show the Organization-Enhanced name(s) 19 Aarhus Univ, Dept Publ Hlth, Sect Environm Occupat & Hlth, Aarhus, Denmark 20 Ctr Rech Albert Bonniot, Grenoble, France

مصطلحات موضوعية: Öndunarfærasjúkdómar, Ofnæmi, Dreifbýli, PAD12, Lung Diseases, Rhinitis, Allergic, Rural Population, envir, socio

الوصف: To access publisher's full text version of this article click on the hyperlink below ; Evidence has suggested that exposure to environmental or microbial biodiversity in early life may impact subsequent lung function and allergic disease risk. ; To investigate the influence of childhood living environment and biodiversity indicators on atopy, asthma and lung function in adulthood. ; The European Community Respiratory Health Survey II investigated ∼10 201 participants aged 26-54 years from 14 countries, including participants' place of upbringing (farm, rural environment or inner city) before age 5 years. A 'biodiversity score' was created based on childhood exposure to cats, dogs, day care, bedroom sharing and older siblings. Associations with lung function, bronchial hyper-responsiveness (BHR), allergic sensitisation, asthma and rhinitis were analysed. ; As compared with a city upbringing, those with early-life farm exposure had less atopic sensitisation (adjusted OR 0.46, 95% CI 0.37 to 0.58), atopic BHR (0.54 (0.35 to 0.83)), atopic asthma (0.47 (0.28 to 0.81)) and atopic rhinitis (0.43 (0.32 to 0.57)), but not non-atopic outcomes. Less pronounced protective effects were observed for rural environment exposures. Women with a farm upbringing had higher FEV1 (adjusted difference 110 mL (64 to 157)), independent of sensitisation and asthma. In an inner city environment, a higher biodiversity score was related to less allergic sensitisation. ; This is the first study to report beneficial effects of growing up on a farm on adult FEV1. Our study confirmed the beneficial effects of early farm life on sensitisation, asthma and rhinitis, and found a similar association for BHR. In persons with an urban upbringing, a higher biodiversity score predicted less allergic sensitisation, but to a lesser magnitude than a childhood farm environment. ; Institut Municipal d'Investigac oMedica (IMIM-IMAS), Uni-versitat Pompeu Fabra (UPF) Imperial College, London University of Pavia King's College, London University of Verona .

العلاقة: http://thorax.bmj.com/content/thoraxjnl/72/3/236.full.pdfTest; http://hdl.handle.net/2336/620151Test

الإتاحة: http://thorax.bmj.com/content/thoraxjnl/72/3/236.full.pdfTest
http://hdl.handle.net/2336/620151Test

المؤلفون: Russell, Melissa A., Janson, Christer, Real, Francisco Gómez, Johannessen, Ane, Waatevik, Marie, Benediktsdóttir, Bryndis, Holm, Mathias, Lindberg, Eva, Schlünssen, Vivi, Raza, Wasif, Dharmage, Shyamali C., Svanes, Cecilie

المساهمون: 1 Univ Melbourne, Sch Populat & Global Hlth, Allergy & Lung Hlth Unit, Ctr Epidemiol & Biostat, Level 3,207 Bouverie St, Melbourne, Vic 3010, Australia Show more 2 Murdoch Childrens Res Inst, Gastro Food Allergy Grp, Melbourne, Vic, Australia 3 Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Uppsala, Sweden Show more 4 Univ Bergen, Dept Clin Sci, Bergen, Norway Show more 5 Haukeland Hosp, Dept Gynaecol & Obstet, Bergen, Norway Show more 6 Univ Bergen, Ctr Int Hlth, Bergen, Norway Show more 7 Haukeland Hosp, Ctr Clin Res, Bergen, Norway Show more 8 Univ Iceland, Fac Med, Reykjavik, Iceland Show more 9 Natl Univ Hosp Iceland, Dept Resp Med & Sleep, Reykjavik, Iceland Show more 10 Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Gothenburg, Sweden Show more 11 Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark 12 Natl Res Ctr Working Environm, Copenhagen, Denmark Show more 13 Umea Univ, Dept Publ Hlth & Clin Med, Div Occupat & Environm Med, Umea, Sweden Show more 14 Haukeland Hosp, Dept Occupat Med, Bergen, Norway, Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Australia, Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden, Department of Clinical Science, University of Bergen, Bergen, Norway, Center for International Health, University of Bergen, Bergen, Norway, Center for Clinical Research, Haukeland University Hospital, Bergen, Norway, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Department of Occupational and Environmental Medicine, Sahlgrenska University Hospital, Göteborg, Sweden, Department of Public Health, Aarhus University, Aarhus, Denmark, Division of Occupational and Environmental Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden

مصطلحات موضوعية: Asma, Líkamsrækt, PAD12, Asthma, Exercise, Adult

الوصف: To access publisher's full text version of this article click on the hyperlink below ; Objective: To investigate the impact of physical activity on asthma in middle-aged adults, in one longitudinal analysis, and one multi-centre cross-sectional analysis. Methods: The Respiratory Health in Northern Europe (RHINE) is a population-based postal questionnaire cohort study. Physical activity, height and weight were self-reported in Bergen, Norway, at RHINE II (1999-2001) and all centres at RHINE III (2010-2012). A longitudinal analysis of Bergen data investigated the association of baseline physical activity with follow-up asthma, incident asthma and symptoms, using logistic and zero-inflated Poisson regression (n = 1782). A cross-sectional analysis of all RHINE III centres investigated the association of physical activity with concurrent asthma and symptoms (n = 13,542) using mixed-effects models. Body mass index (BMI) was categorised (<20, 20-24.99, 25-29.99, 30+ kg/m(2)) and physical activity grouped by amount and frequency of lighter (no sweating/heavy breathing) and vigorous (sweating/heavy breathing) activity. Results: In the Bergen longitudinal analysis, undertaking light activity 3+ times/week at baseline was associated with less follow-up asthma (odds ratio [OR] 0.44, 95% confidence interval [CI] 0.22, 0.89), whilst an effect from undertaking vigorous activity 3+ times/week was not detected (OR 1.22, 95% CI 0.44, 2.76). The associations were attenuated with BMI adjustment. In the all-centre cross-sectional analysis an interaction was found, with the association between physical activity and asthma varying across BMI categories. Conclusion: These findings suggest potential longer-term benefit from lighter physical activity, whilst improvement in asthma outcomes from increasing activity intensity was not evident. Additionally, it appears the benefit from physical activity may differ according to BMI. ; Norwegian Research Council Bergen Medical Research Foundation Western Norwegian Regional Health Authorities ...

العلاقة: Physical activity and asthma: A longitudinal and multi-country study 2017, 54 (9):938 Journal of Asthma; http://hdl.handle.net/2336/620410Test; Journal of Asthma

الإتاحة: https://doi.org/10.1080/02770903.2017.1281293Test
http://hdl.handle.net/2336/620410Test

المؤلفون: Jensson, Brynjar O., Hansdottir, Sif, Arnadottir, Gudny A., Sulem, Gerald, Kristjansson, Ragnar P., Oddsson, Asmundur, Benonisdottir, Stefania, Jonsson, Hakon, Helgason, Agnar, Saemundsdottir, Jona, Magnusson, Olafur T., Masson, Gisli, Thorisson, Gudmundur A., Jonasdottir, Adalbjorg, Jonasdottir, Aslaug, Sigurdsson, Asgeir, Jonsdottir, Ingileif, Petursdottir, Vigdis, Kristinsson, Jon R., Gudbjartsson, Daniel F., Thorsteinsdottir, Unnur, Arngrimsson, Reynir, Sulem, Patrick, Gudmundsson, Gunnar, Stefansson, Kari

المساهمون: 1 Amgen Inc, deCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland Show more 2 Landspitali Univ Hosp, Dept Resp Med & Sleep, Reykjavik, Iceland Show more 3 Univ Iceland, Dept Anthropol, Reykjavik, Iceland Show more 4 Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland Show more 5 Landspitali Univ Hosp, Dept Pediat, Reykjavik, Iceland Show more 6 Univ Iceland, Sch Engn & Nat Sci, Reykjavik, Iceland Show more 7 Univ Iceland, Fac Med, Reykjavik, Iceland Show more 8 Landspitali Univ Hosp, Dept Genet & Mol Med, Reykjavik, Iceland Show more 9 Univ Iceland, Dept Biochem & Mol Biol, Reykjavik, Iceland

مصطلحات موضوعية: Ónæmiskerfi, Gen, Lungnasjúkdómar, Nýrnasjúkdómar, PAD12, PTT12, PED12, AAI12, Coatomer Protein, Lung Diseases, Arthritis, Immunologic Deficiency Syndromes

الوصف: To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files ; Background: Rare missense mutations in the gene encoding coatomer subunit alpha (COPA) have recently been shown to cause autoimmune interstitial lung, joint and kidney disease, also known as COPA syndrome, under a dominant mode of inheritance. Case presentation: Here we describe an Icelandic family with three affected individuals over two generations with a rare clinical presentation of lung and joint disease and a histological diagnosis of follicular bronchiolitis. We performed whole-genome sequencing (WGS) of the three affected as well as three unaffected members of the family, and searched for rare genotypes associated with disease using 30,067 sequenced Icelanders as a reference population. We assessed all coding and splicing variants, prioritizing variants in genes known to cause interstitial lung disease. We detected a heterozygous missense mutation, p.Glu241Lys, in the COPA gene, private to the affected family members. The mutation occurred de novo in the paternal germline of the index case and was absent from 30,067 Icelandic genomes and 141,353 individuals from the genome Aggregation Database (gnomAD). The mutation occurs within the conserved and functionally important WD40 domain of the COPA protein. Conclusions: This is the second report of the p.Glu241Lys mutation in COPA, indicating the recurrent nature of the mutation. The mutation was reported to co-segregate with COPA syndrome in a large family from the USA with five affected members, and classified as pathogenic. The two separate occurrences of the p.Glu241Lys mutation in cases and its absence from a large number of sequenced genomes confirms its role in the pathogenesis of the COPA syndrome.

العلاقة: https://bmcmedgenet.biomedcentral.com/articles/10.1186/s12881-017-0490-8Test; COPA syndrome in an Icelandic family caused by a recurrent missense mutation in COPA 2017, 18 (1):129 BMC Medical Genetics; http://hdl.handle.net/2336/620418Test; BMC Medical Genetics

الإتاحة: https://doi.org/10.1186/s12881-017-0490-8Test
http://hdl.handle.net/2336/620418Test

المؤلفون: Lindberg, Eva, Benediktsdottir, Bryndis, Franklin, Karl A, Holm, Mathias, Johannessen, Ane, Jögi, Rain, Gislason, Thorarinn, Real, Francisco Gomez, Schlünssen, Vivi, Janson, Christer

المساهمون: 1 Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Uppsala, Sweden Show the Organization-Enhanced name(s) 2 Natl Univ Hosp Iceland, Dept Resp Med & Sleep, Reykjavik, Iceland Show the Organization-Enhanced name(s) 3 Univ Iceland, Fac Med, Reykjavik, Iceland Show the Organization-Enhanced name(s) 4 Umea Univ, Dept Surg & Petioperat Sci, Surg, Umea, Sweden Show the Organization-Enhanced name(s) 5 Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Gothenburg, Sweden Show the Organization-Enhanced name(s) 6 Univ Bergen, Ctr Int Hlth, Dept Global Publ Hlth & Primary Care, Bergen, Norway Show the Organization-Enhanced name(s) 7 Tartu Univ Clin, Lung Clin, Tartu, Estonia Show the Organization-Enhanced name(s) 8 Haukeland Hosp, Dept Gynecol & Obstet, Bergen, Norway Show the Organization-Enhanced name(s) 9 Aarhus Univ, Sect Environm Occupat & Hlth, Dept Publ Hlth, Aarhus, Denmark 10 Natl Res Ctr Working Environm, Copenhagen, Denmark

مصطلحات موضوعية: Kæfisvefn, Svefntruflanir, Hrotur, Konur, PAD12, Sleep Apnea Syndromes, Snoring, Women

الوصف: To access publisher's full text version of this article click on the hyperlink below ; Women are often underrepresented at sleep clinics evaluating sleep-disordered breathing (SDB). The aim of the present study was to analyze gender differences in sleep apnea diagnosis and treatment in men and women with similar symptoms of SDB. ; Respiratory Health in Northern Europe (RHINE) provided information about snoring, excessive daytime sleepiness (EDS), BMI and somatic diseases at baseline (1999-2001) and follow-up (2010-2012) from 4962 men and 5892 women. At follow-up participants were asked whether they had a diagnosis of and/or treatment for sleep apnea. ; Among those with symptoms of SDB (snoring and EDS), more men than women had been given the diagnosis of sleep apnea (25% vs. 14%, p < 0.001), any treatment (17% vs. 11%, p = 0.05) and CPAP (6% vs. 3%, p = 0.04) at follow-up. Predictors of receiving treatment were age, BMI, SDB symptoms at baseline and weight gain, while female gender was related to a lower probability of receiving treatment (adj. OR 0.3, 95% CI 0.3-0.5). In both genders, the symptoms of SDB increased the risk of developing hypertension (adj OR, 95% CI: 1.5, 1.2-1.8) and diabetes (1.5, 1.05-2.3), independent of age, BMI, smoking and weight gain. ; Snoring females with daytime sleepiness may be under-diagnosed and under-treated for sleep apnea compared with males, despite running a similar risk of developing hypertension and diabetes. ; Norwegian Research Council Icelandic Research Council Aarhus universitet Swedish Heart-Lung Foundation Estonian Science Foundation

العلاقة: http://ac.els-cdn.com/S1389945717301752/1-s2.0-S1389945717301752-main.pdf?_tid=3b5fb7e8-8be1-11e7-b39c-00000aab0f6b&acdnat=1503918694_ec560d3515598cd3193ae472db39c659Test; Women with symptoms of sleep-disordered breathing are less likely to be diagnosed and treated for sleep apnea than men. 2017, 35:17-22 Sleep Med.; http://hdl.handle.net/2336/620282Test; Sleep medicine

الإتاحة: https://doi.org/10.1016/j.sleep.2017.02.032Test
http://hdl.handle.net/2336/620282Test

المؤلفون: Svanes, Cecilie, Koplin, Jennifer, Skulstad, Svein Magne, Johannessen, Ane, Bertelsen, Randi Jakobsen, Benediktsdottir, Byndis, Bråbäck, Lennart, Elie Carsin, Anne, Dharmage, Shyamali, Dratva, Julia, Forsberg, Bertil, Gislason, Thorarinn, Heinrich, Joachim, Holm, Mathias, Janson, Christer, Jarvis, Deborah, Jögi, Rain, Krauss-Etschmann, Susanne, Lindberg, Eva, Macsali, Ferenc, Malinovschi, Andrei, Modig, Lars, Norbäck, Dan, Omenaas, Ernst, Waatevik Saure, Eirunn, Sigsgaard, Torben, Skorge, Trude Duelien, Svanes, Øistein, Torén, Kjell, Torres, Carl, Schlünssen, Vivi, Gomez Real, Francisco

المساهمون: 1 Centre for International Health, University of Bergen, Norway. 2 Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway. 3 Department of Clinical Science, University of Bergen, Norway. 4 School of Population and Global Health, University of Melbourne, Australia. 5 Murdoch Childrens Research Institute, Melbourne, Australia. 6 Department of Obstetrics, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 7 Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway. 8 Department of Allergy, Respiratory Medicine and Sleep, Landspitali University Hospital, Reykjavik, Iceland. 9 University of Iceland, Medical Faculty. 10 Occupational and Environmental Medicine, Department of Public Health and Clinical Medicine, Umeå University, Sweden. 11 Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain. 12 Department of Epidemiology and Public Health, Gender & Health, Swiss Tropical and Public Health Institute, Basel University, Switzerland. 13 Institute of Epidemiology I, Helmholtz Zentrum, Munich, Germany. 14 Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden. 15 Department of Medical Sciences, Uppsala University, Sweden. 16 Faculty of Medicine, National Heart & Lung Institute, Imperial College, London, UK. 17 Lung Clinic, Foundation Tartu University Clinics, Tartu, Estonia. 18 Department of Pulmonary Medicine, Tartu University, Estonia. 19 Research Center Borstel, Leibniz-Center for Medicine and Biosciences, Divison of Experimental Asthma Research, University of Kiel, Germany. 20 Department of Obstetrics and Gynecology, Haukeland, University Hospital, Bergen, Norway. 21 Department of Public Health, Aarhus University, Denmark.

مصطلحات موضوعية: Asma, Börn, Feður, Umhverfisáhrif, PAD12, AAI12, Asthma, Occupational Exposure, Environmental Exposure, Smoking, Fathers

الوصف: To access publisher's full text version of this article click on the hyperlink below ; Whereas it is generally accepted that maternal environment plays a key role in child health, emerging evidence suggests that paternal environment before conception also impacts child health. We aimed to investigate the association between children's asthma risk and parental smoking and welding exposures prior to conception. ; In a longitudinal, multi-country study, parents of 24 168 offspring aged 2-51 years provided information on their life-course smoking habits, occupational exposure to welding and metal fumes, and offspring's asthma before/after age 10 years and hay fever. Logistic regressions investigated the relevant associations controlled for age, study centre, parental characteristics (age, asthma, education) and clustering by family. ; Non-allergic early-onset asthma (asthma without hay fever, present in 5.8%) was more common in the offspring with fathers who smoked before conception {odds ratio [OR] = 1.68 [95% confidence interval (CI) = 1.18-2.41]}, whereas mothers' smoking before conception did not predict offspring asthma. The risk was highest if father started smoking before age 15 years [3.24 (1.67-6.27)], even if he stopped more than 5 years before conception [2.68 (1.17-6.13)]. Fathers' pre-conception welding was independently associated with non-allergic asthma in his offspring [1.80 (1.29-2.50)]. There was no effect if the father started welding or smoking after birth. The associations were consistent across countries. ; Environmental exposures in young men appear to influence the respiratory health of their offspring born many years later. Influences during susceptible stages of spermatocyte development might be important and needs further investigation in humans. We hypothesize that protecting young men from harmful exposures may lead to improved respiratory health in future generations. ; Norwegian Research Council Bergen Medical Research Foundation Western Norwegian Regional Health Authorities Norwegian ...

العلاقة: http://www.wun.ac.uk/files/2016_Svanes_Koplin_IJE_father_preconception_smoking.pdfTest; Father's environment before conception and asthma risk in his children: a multi-generation analysis of the Respiratory Health In Northern Europe study. 2017, 46 (1):235-245 Int J Epidemiol; http://hdl.handle.net/2336/620246Test; International journal of epidemiology

الإتاحة: https://doi.org/10.1093/ije/dyw151Test
http://hdl.handle.net/2336/620246Test

المؤلفون: Oskarsdottir, G N, Halldorsson, H, Sigurdsson, M I, Fridriksson, B M, Baldvinsson, K, Orrason, A W, Jonsson, S, Planck, M, Gudbjartsson, T

المساهمون: 1 Landspitali Univ Hosp, Dept Cardiothorac Surg, Reykjavik, Iceland Show the Organization-Enhanced name(s) 2 Skane Univ Hosp, Dept Pulmonol, Lund, Sweden Show the Organization-Enhanced name(s) 3 Landspitali Univ Hosp, Dept Pulmonol, Reykjavik, Iceland Show the Organization-Enhanced name(s) 4 Univ Iceland, Fac Med, Reykjavik, Iceland

مصطلحات موضوعية: Lungnakrabbamein, Brjóstholsskurðlækningar, Skurðlækningar, Lífslíkur, TAS12, PAD12, Pulmonary Surgical Procedures, Patient Outcome Assessment, Survival, Carcinoma, Non-Small-Cell Lung

الوصف: Lobectomy is the standard curative treatment for non-small cell carcinoma (NSCLC) of the lung. Most studies on lobectomy have focused on short-term outcome and 30-day mortality. The aim of this study was to determine both short-term and long-term surgical outcome in all patients who underwent lobectomy for NSCLC in Iceland over a 24-year period. ; The study involved 489 consecutive patients with NSCLC who underwent lobectomy with curative intent in Iceland, 1991-2014. Patient demographics, pTNM stage, rate of perioperative complications, and 30-day mortality were registered. Overall survival was analyzed with the Kaplan?Meier method. The Cox proportional hazards model was used to evaluate factors that were prognostic of overall mortality. To study trends in survival, the study period was divided into six 4-year periods. The median follow-up time was 42 months and no patients were lost to follow-up. ; The average age of the patients was 67 years and 53.8% were female. The pTNM disease stage was IA in 148 patients (30.0%), IB in 125 patients (25.4%), IIA in 96 patients (19.5%), and IIB in 50 patients (10.1%), but 74 (15.0%) were found to be stage IIIA, most often diagnosed perioperatively. The total rate of major complications was 4.7%. Thirty-day mortality was 0.6% (three patients). One- and 5-year overall survival was 85.0% and 49.2%, respectively, with 3-year survival improving from 48.3% to 72.8% between the periods 1991-1994 and 2011-2014 (p = .0004). Advanced TNM stage and age were independent negative prognostic factors for all-cause mortality, and later calendar year and free surgical margins were independent predictors of improved survival. ; The short-term outcome of lobectomy for NSCLC in this population-based study was excellent, as reflected in the low 30-day mortality and low rate of major complications. The long-term survival was acceptable and the overall 3-year survival had improved significantly during the study period. ; Landspitali University Hospital Research Fund University of Iceland ...

العلاقة: Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival. 2017, 56 (7):936-942 Acta Oncol; http://hdl.handle.net/2336/620219Test; Acta oncologica (Stockholm, Sweden)

الإتاحة: https://doi.org/10.1080/0284186X.2017.1304652Test
http://hdl.handle.net/2336/620219Test

المؤلفون: Wain, Louise V, Shrine, Nick, Artigas, María Soler, Erzurumluoglu, A Mesut, Noyvert, Boris, Bossini-Castillo, Lara, Obeidat, Ma'en, Henry, Amanda P, Portelli, Michael A, Hall, Robert J, Billington, Charlotte K, Rimington, Tracy L, Fenech, Anthony G, John, Catherine, Blake, Tineka, Jackson, Victoria E, Allen, Richard J, Prins, Bram P, Campbell, Archie, Porteous, David J, Jarvelin, Marjo-Riitta, Wielscher, Matthias, James, Alan L, Hui, Jennie, Wareham, Nicholas J, Zhao, Jing Hua, Wilson, James F, Joshi, Peter K, Stubbe, Beate, Rawal, Rajesh, Schulz, Holger, Imboden, Medea, Probst-Hensch, Nicole M, Karrasch, Stefan, Gieger, Christian, Deary, Ian J, Harris, Sarah E, Marten, Jonathan, Rudan, Igor, Enroth, Stefan, Gyllensten, Ulf, Kerr, Shona M, Polasek, Ozren, Kähönen, Mika, Surakka, Ida, Vitart, Veronique, Hayward, Caroline, Lehtimäki, Terho, Raitakari, Olli T, Evans, David M, Henderson, A John, Pennell, Craig E, Wang, Carol A, Sly, Peter D, Wan, Emily S, Busch, Robert, Hobbs, Brian D, Litonjua, Augusto A, Sparrow, David W, Gulsvik, Amund, Bakke, Per S, Crapo, James D, Beaty, Terri H, Hansel, Nadia N, Mathias, Rasika A, Ruczinski, Ingo, Barnes, Kathleen C, Bossé, Yohan, Joubert, Philippe, van den Berge, Maarten, Brandsma, Corry-Anke, Paré, Peter D, Sin, Don D, Nickle, David C, Hao, Ke, Gottesman, Omri, Dewey, Frederick E, Bruse, Shannon E, Carey, David J, Kirchner, H Lester, Jonsson, Stefan, Thorleifsson, Gudmar, Jonsdottir, Ingileif, Gislason, Thorarinn, Stefansson, Kari, Schurmann, Claudia, Nadkarni, Girish, Bottinger, Erwin P, Loos, Ruth J F, Walters, Robin G, Chen, Zhengming, Millwood, Iona Y, Vaucher, Julien, Kurmi, Om P, Li, Liming, Hansell, Anna L, Brightling, Chris, Zeggini, Eleftheria, Cho, Michael H, Silverman, Edwin K, Sayers, Ian, Trynka, Gosia, Morris, Andrew P, Strachan, David P, Hall, Ian P, Tobin, Martin D

المساهمون: 1 Univ Leicester, Dept Hlth Sci, Leicester, Leics, England Show the Organization-Enhanced name(s) 2 Glenfield Hosp, Natl Inst Hlth Res, Leicester Resp Biomed Res Unit, Leicester, Leics, England Show the Organization-Enhanced name(s) 3 Wellcome Trust Sanger Inst, Hinxton, England Show the Organization-Enhanced name(s) 4 Univ British Columbia, Ctr Heart Lung Innovat, St Pauls Hosp, Vancouver, BC, Canada Show the Organization-Enhanced name(s) 5 Univ Nottingham, Div Resp Med, Nottingham, England Show the Organization-Enhanced name(s) 6 Univ Malta, Dept Clin Pharmacol & Therapeut, Msida, Malta Show the Organization-Enhanced name(s) 7 Wellcome Trust Sanger Inst, Dept Human Genet, Hinxton, England Show the Organization-Enhanced name(s) 8 Univ Edinburgh, Inst Genet & Mol Med, Ctr Genom & Expt Med, Med Genet Sect, Edinburgh, Midlothian, Scotland Show the Organization-Enhanced name(s) 9 Univ Edinburgh, Ctr Genom & Expt Med, Generat Scotland, Edinburgh, Midlothian, Scotland Show the Organization-Enhanced name(s) 10 Imperial Coll London, Sch Publ Hlth, MRC PHE Ctr Environm & Hlth, Dept Epidemiol & Biostat, London, England Show the Organization-Enhanced name(s) 11 Univ Oulu, Ctr Life Course Hlth Res, Fac Med, Oulu, Finland Show the Organization-Enhanced name(s) 12 Univ Oulu, Bioctr Oulu, Oulu, Finland Show the Organization-Enhanced name(s) 13 Oulu Univ Hosp, Unit Primary Care, Oulu, Finland Show the Organization-Enhanced name(s) 14 Sir Charles Gairdner Hosp, Busselton Populat Med Res Inst, Nedlands, WA, Australia Show the Organization-Enhanced name(s) 15 Sir Charles Gairdner Hosp, Dept Pulm Physiol & Sleep Med, Nedlands, WA, Australia Show the Organization-Enhanced name(s) 16 Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia Show the Organization-Enhanced name(s) 17 Univ Western Australia, Sch Populat Hlth, Crawley, WA, Australia 18 Sir Charles Gairdner Hosp, PathWest Lab Med Western Australia, Crawley, WA, Australia Show the Organization-Enhanced name(s) 19 Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia Show the Organization-Enhanced name(s) 20 Univ Cambridge, Sch Clin Med, MRC Epidemiol Unit, Inst Metab Sci, Cambridge Biomed Campus, Cambridge, England Show the Organization-Enhanced name(s) 21 Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Ctr Global Hlth Res, Edinburgh, Midlothian, Scotland Show the Organization-Enhanced name(s) 22 Univ Edinburgh, Inst Genet & Mol Med, MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland 23 Univ Med Greifswald, Dept Internal Med Cardiol Intens Care Pulm Med &, Greifswald, Germany Show the Organization-Enhanced name(s) 24 Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 2, Res Unit Mol Epidemiol, Neuherberg, Germany Show the Organization-Enhanced name(s) 25 Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 1, Neuherberg, Germany 26 German Ctr Lung Res, Comprehens Pneumol Ctr Munich CPC M, Neuherberg, Germany Show the Organization-Enhanced name(s) 27 Swiss Trop & Publ Hlth Inst, Basel, Switzerland Show the Organization-Enhanced name(s) 28 Univ Basel, Basel, Switzerland Show the Organization-Enhanced name(s) 29 Ludwig Maximilians Univ Munchen, Inst & Outpatient Clin Occupat Social & Environm, Munich, Germany Show the Organization-Enhanced name(s) 30 Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland Show the Organization-Enhanced name(s) 31 Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland Show the Organization-Enhanced name(s) 32 Uppsala Univ, Sci Life Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden Show the Organization-Enhanced name(s) 33 Univ Split, Sch Med, Split, Croatia Show the Organization-Enhanced name(s) 34 Univ Tampere, Dept Clin Physiol, Tampere, Finland Show the Organization-Enhanced name(s) 35 Tampere Univ Hosp, Tampere, Finland Show the Organization-Enhanced name(s) 36 Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland Show the Organization-Enhanced name(s) 37 Natl Inst Hlth & Welf THL, Helsinki, Finland Show the Organization-Enhanced name(s) 38 Univ Tampere, Fimlab Labs, Dept Clin Chem, Tampere, Finland Show the Organization-Enhanced name(s) 39 Univ Tampere, Sch Med, Tampere, Finland Show the Organization-Enhanced name(s) 40 Univ Tampere, Sch Med, Dept Clin Chem, Tampere, Finland Show the Organization-Enhanced name(s) 41 Turku Univ Hosp, Dept Clin Physiol & Nucl Med, Turku, Finland Show the Organization-Enhanced name(s) 42 Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland Show the Organization-Enhanced name(s) 43 Univ Queensland, Translat Res Inst, Diamantina Inst, Brisbane, Qld, Australia Show the Organization-Enhanced name(s) 44 Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England Show the Organization-Enhanced name(s) 45 Univ Bristol, Sch Social & Community Med, Bristol, Avon, England Show the Organization-Enhanced name(s) 46 Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA, Australia Show the Organization-Enhanced name(s) 47 Univ Queensland, Fac Med, Child Hlth Res Ctr, Brisbane, Qld, Australia Show the Organization-Enhanced name(s) 48 Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA Show the Organization-Enhanced name(s) 49 Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA Show the Organization-Enhanced name(s) 50 VA Boston Healthcare Syst, Boston, MA USA Show the Organization-Enhanced name(s) 51 Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA Show the Organization-Enhanced name(s) 52 Univ Bergen, Dept Clin Sci, Bergen, Norway Show the Organization-Enhanced name(s) 53 Natl Jewish Hlth, Denver, CO USA Show the Organization-Enhanced name(s) 54 Natl Jewish Hlth, Div Pulm Crit Care & Sleep Med, Denver, CO USA Show the Organization-Enhanced name(s) 55 Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA Show the Organization-Enhanced name(s) 56 Johns Hopkins Univ, Sch Med, Pulm & Crit Care Med, Baltimore, MD USA Show the Organization-Enhanced name(s) 57 Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA Show the Organization-Enhanced name(s) 58 Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA Show the Organization-Enhanced name(s) 59 Univ Colorado, Sch Med, Dept Med, Div Biomed Informat & Personalized Med, Anschutz Med Campus, Aurora, CO USA Show the Organization-Enhanced name(s) 60 Univ Laval, Dept Mol Med, Quebec City, PQ, Canada Show the Organization-Enhanced name(s) 61 Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada Show the Organization-Enhanced name(s) 62 Univ Laval, Dept Mol Biol Med Biochem & Pathol, Quebec City, PQ, Canada Show the Organization-Enhanced name(s) 63 Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, GRIAC Res Inst, Groningen, Netherlands Show the Organization-Enhanced name(s) 64 Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, GRIAC Res Inst, Groningen, Netherlands Show the Organization-Enhanced name(s) 65 Univ British Columbia, Dept Med, Resp Div, Vancouver, BC, Canada Show the Organization-Enhanced name(s) 66 Merck Res Labs, Genet & Pharmacogen, Boston, MA USA 67 Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA Show the Organization-Enhanced name(s) 68 Regeneron Pharmaceut Inc, Regeneron Genet Ctr, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA 69 Geisinger Hlth Syst, Danville, PA USA 70 deCODE Genet Amgen Inc, Reykjavik, Iceland Show the Organization-Enhanced name(s) 71 Univ Iceland, Fac Med, Sch Hlth Sci, Reykjavik, Iceland Show the Organization-Enhanced name(s) 72 Landspitali Univ Hosp Reykjavik, Dept Resp Med & Sleep, Reykjavik, Iceland 73 Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA 74 Icahn Sch Med Mt Sinai, Genet Obes & Related Metab Traits Program, New York, NY 10029 USA 75 Icahn Sch Med Mt Sinai, Mindich Child Hlth Dev Inst, New York, NY 10029 USA Show the Organization-Enhanced name(s) 76 Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England Show the Organization-Enhanced name(s) 77 Univ Oxford, Nuffield Dept Populat Hlth, Epidemiol Studies Unit CTSU, Oxford, England Show the Organization-Enhanced name(s) 78 Univ Oxford, MRC, Populat Hlth Res Unit, Oxford, England Show the Organization-Enhanced name(s) 79 Chinese Acad Med Sci, Beijing, Peoples R China Show the Organization-Enhanced name(s) 80 Peking Univ, Hlth Sci Ctr, Dept Epidemiol & Biostat, Beijing, Peoples R China Show the Organization-Enhanced name(s) 81 Imperial Coll London, Sch Publ Hlth, MRC PHE Ctr Environm & Hlth, UK Small Area Hlth Stat Unit, London, England Show the Organization-Enhanced name(s) 82 Imperial Coll Healthcare NHS Trust, St Marys Hosp, London, England Show the Organization-Enhanced name(s) 83 Univ Leicester, Inst Lung Hlth, Dept Infect Inflammat & Immun, Leicester, Leics, England Show the Organization-Enhanced name(s) 84 Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England Show the Organization-Enhanced name(s) 85 St Georges Univ London, Populat Hlth Res Inst, London, England

مصطلحات موضوعية: Langvinn lungnateppa, PAD12, Pulmonary Disease, Chronic Obstructive, Genome-Wide Association Study

الوصف: Chronic obstructive pulmonary disease (COPD) is characterized by reduced lung function and is the third leading cause of death globally. Through genome-wide association discovery in 48,943 individuals, selected from extremes of the lung function distribution in UK Biobank, and follow-up in 95,375 individuals, we increased the yield of independent signals for lung function from 54 to 97. A genetic risk score was associated with COPD susceptibility (odds ratio per 1 s.d. of the risk score (∼6 alleles) (95% confidence interval) = 1.24 (1.20-1.27), P = 5.05 × 10(-49)), and we observed a 3.7-fold difference in COPD risk between individuals in the highest and lowest genetic risk score deciles in UK Biobank. The 97 signals show enrichment in genes for development, elastic fibers and epigenetic regulation pathways. We highlight targets for drugs and compounds in development for COPD and asthma (genes in the inositol phosphate metabolism pathway and CHRM3) and describe targets for potential drug repositioning from other clinical indications. ; Medical Research Council (MRC) National Institute for Health Research (NIHR)

العلاقة: http://www.nature.com/ng/journal/v49/n3/pdf/ng.3787.pdfTest; Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. 2017, 49 (3):416-425 Nat. Genet.; http://hdl.handle.net/2336/620143Test; Nature genetics

الإتاحة: https://doi.org/10.1038/ng.3787Test
http://hdl.handle.net/2336/620143Test

المؤلفون: Eysteinsdottir, Bjorg, Gislason, Thorarinn, Pack, Allan I, Benediktsdottir, Bryndís, Arnardottir, Erna S, Kuna, Samuel T, Björnsdottir, Erla

المساهمون: 1 Landspitali, Dept Resp Med & Sleep, Reykjavik, Iceland Show the Organization-Enhanced name(s) 2 Univ Iceland, Fac Med, Reykjavik, Iceland Show the Organization-Enhanced name(s) 3 Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA Show the Organization-Enhanced name(s) 4 Univ Penn, Perelman Sch Med, Dept Med, Div Sleep Med, Philadelphia, PA 19104 USA 5 Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA

مصطلحات موضوعية: Kæfisvefn, Svefnleysi, PAD12, Sleep Apnea, Obstructive, Sleep Initiation and Maintenance Disorders, Patient Compliance

الوصف: To access publisher's full text version of this article click on the hyperlink below ; The objective of this study was to evaluate the determinants of long-term adherence to positive airway pressure treatment among patients with obstructive sleep apnea, with special emphasis on patients who stop positive airway pressure treatment within 1 year. This is a prospective long-term follow-up of subjects in the Icelandic Sleep Apnea Cohort who were diagnosed with obstructive sleep apnea between 2005 and 2009, and started on positive airway pressure treatment. In October 2014, positive airway pressure adherence was obtained by systematically evaluating available clinical files (n = 796; 644 males, 152 females) with moderate to severe obstructive sleep apnea (apnea-hypopnea index ≥15 events per h). The mean follow-up time was 6.7 ± 1.2 years. In total, 123 subjects (15.5%) returned their positive airway pressure device within the first year, 170 (21.4%) returned it later and 503 (63.2%) were still using positive airway pressure. The quitters within the first year had lower body mass index, milder obstructive sleep apnea, less sleepiness, and more often had symptoms of initial and late insomnia compared with long-term positive airway pressure users at baseline. Both initial and late insomnia were after adjustment still significantly associated with being an early quitter among subjects with body mass index <30 kg m(-2) , but not among those with body mass index ≥30 kg m(-2) . The prevalence of early quitters decreased significantly during the study period (2005-2009). Almost two-thirds of patients with moderate to severe obstructive sleep apnea are positive airway pressure users after 7 years. Obesity level, obstructive sleep apnea severity and daytime sleepiness are important determinants of long-term adherence. Symptoms of initial and late insomnia are associated with early quitting on positive airway pressure among non-obese subjects. ; NIH

العلاقة: Insomnia complaints in lean patients with obstructive sleep apnea negatively affect positive airway pressure treatment adherence. 2017, 26 (2):159-165 J Sleep Res; http://hdl.handle.net/2336/620180Test; Journal of sleep research

الإتاحة: https://doi.org/10.1111/jsr.12482Test
http://hdl.handle.net/2336/620180Test